Acticam

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
24-03-2021
Karakteristik produk Karakteristik produk (SPC)
24-03-2021

Bahan aktif:

meloxicam

Tersedia dari:

Ecuphar

Kode ATC:

QM01AC06

INN (Nama Internasional):

meloxicam

Kelompok Terapi:

Dogs; Cats

Area terapi:

Anti inflammatory and antirheumatic products

Indikasi Terapi:

Oral suspension:Dogs:Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Solution for injection:Dogs:Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.Cats:Reduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.

Ringkasan produk:

Revision: 9

Status otorisasi:

Withdrawn

Tanggal Otorisasi:

2008-12-09

Selebaran informasi

                                Medicinal product no longer authorised
14
B. PACKAGE LEAFLET
Medicinal product no longer authorised
15
PACKAGE LEAFLET:
ACTICAM 5 MG/ML SOLUTION FOR INJECTION FOR DOGS AND CATS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Ecuphar NV
Legeweg 157-i
B-8020 Oostkamp
Belgium
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Acticam 5 mg/ml solution for injection for dogs and cats.
Meloxicam.
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Meloxicam 5 mg/ml.
Ethanol anhydrous 150 mg/ml.
4.
INDICATION(S)
Dogs:
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders. Reduction
of post-operative pain and inflammation following orthopaedic and soft
tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor
soft tissue surgery.
5.
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such
as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less
than 2 kg.
6.
ADVERSE REACTIONS
Typical adverse reactions of NSAIDs such as loss of appetite,
vomiting, diarrhoea, faecal occult blood,
lethargy and renal failure have occasionally been reported. In very
rare cases elevated liver enzymes
have been reported. In dogs, in very rare cases, haemorrhagic
diarrhoea, haematemesis and
gastrointestinal ulceration have been reported. In dogs, these side
effects occur generally within the
first treatment week and are in most cases transient and disappear
following termination of the
treatment but in very rare cases may be serious or fatal. In very rare
cases anaphylactoid reactions may
occur and should be treated symptomatically.
Medicinal product no longer authorised
16
If adverse reactions occur
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Acticam 5 mg/ml solution for injection for dogs and cats.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Meloxicam 5 mg.
EXCIPIENTS:
Ethanol, anhydrous 150 mg.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
A clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Dogs:
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders. Reduction
of post-operative pain and inflammation following orthopaedic and soft
tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor
soft tissue surgery.
4.3
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such
as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less
than 2 kg.
Do not use an oral follow-up therapy using meloxicam or other NSAIDs
in cats, as no safe dosage for
repeated oral administration has been established.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
For post-operative pain relief in cats, safety has only been
documented after thiopental/halothane
anaesthesia.
Medicinal product no longer authorised
3
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If side effects occur, treatment should be discontinued.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a potential risk of
increased renal toxicity.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
Accidental self-injection may give rise to pain.
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 24-03-2021
Karakteristik produk Karakteristik produk Bulgar 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Bulgar 24-03-2021
Selebaran informasi Selebaran informasi Spanyol 24-03-2021
Karakteristik produk Karakteristik produk Spanyol 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Spanyol 24-03-2021
Selebaran informasi Selebaran informasi Cheska 24-03-2021
Karakteristik produk Karakteristik produk Cheska 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Cheska 24-03-2021
Selebaran informasi Selebaran informasi Dansk 24-03-2021
Karakteristik produk Karakteristik produk Dansk 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Dansk 24-03-2021
Selebaran informasi Selebaran informasi Jerman 24-03-2021
Karakteristik produk Karakteristik produk Jerman 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Jerman 24-03-2021
Selebaran informasi Selebaran informasi Esti 24-03-2021
Karakteristik produk Karakteristik produk Esti 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Esti 24-03-2021
Selebaran informasi Selebaran informasi Yunani 24-03-2021
Karakteristik produk Karakteristik produk Yunani 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Yunani 24-03-2021
Selebaran informasi Selebaran informasi Prancis 24-03-2021
Karakteristik produk Karakteristik produk Prancis 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Prancis 24-03-2021
Selebaran informasi Selebaran informasi Italia 24-03-2021
Karakteristik produk Karakteristik produk Italia 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Italia 24-03-2021
Selebaran informasi Selebaran informasi Latvi 24-03-2021
Karakteristik produk Karakteristik produk Latvi 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Latvi 24-03-2021
Selebaran informasi Selebaran informasi Lituavi 24-03-2021
Karakteristik produk Karakteristik produk Lituavi 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Lituavi 24-03-2021
Selebaran informasi Selebaran informasi Hungaria 24-03-2021
Karakteristik produk Karakteristik produk Hungaria 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Hungaria 24-03-2021
Selebaran informasi Selebaran informasi Malta 24-03-2021
Karakteristik produk Karakteristik produk Malta 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Malta 24-03-2021
Selebaran informasi Selebaran informasi Belanda 24-03-2021
Karakteristik produk Karakteristik produk Belanda 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Belanda 24-03-2021
Selebaran informasi Selebaran informasi Polski 24-03-2021
Karakteristik produk Karakteristik produk Polski 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Polski 24-03-2021
Selebaran informasi Selebaran informasi Portugis 24-03-2021
Karakteristik produk Karakteristik produk Portugis 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Portugis 24-03-2021
Selebaran informasi Selebaran informasi Rumania 24-03-2021
Karakteristik produk Karakteristik produk Rumania 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Rumania 24-03-2021
Selebaran informasi Selebaran informasi Slovak 24-03-2021
Karakteristik produk Karakteristik produk Slovak 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Slovak 24-03-2021
Selebaran informasi Selebaran informasi Sloven 24-03-2021
Karakteristik produk Karakteristik produk Sloven 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Sloven 24-03-2021
Selebaran informasi Selebaran informasi Suomi 24-03-2021
Karakteristik produk Karakteristik produk Suomi 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Suomi 24-03-2021
Selebaran informasi Selebaran informasi Swedia 24-03-2021
Karakteristik produk Karakteristik produk Swedia 24-03-2021
Laporan Penilaian publik Laporan Penilaian publik Swedia 24-03-2021
Selebaran informasi Selebaran informasi Norwegia 24-03-2021
Karakteristik produk Karakteristik produk Norwegia 24-03-2021
Selebaran informasi Selebaran informasi Islandia 24-03-2021
Karakteristik produk Karakteristik produk Islandia 24-03-2021
Selebaran informasi Selebaran informasi Kroasia 24-03-2021
Karakteristik produk Karakteristik produk Kroasia 24-03-2021

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen